RESULTS:
A total of 570 donors (290 in Group 1, 134 in Group 2, 146 Group 3) were selected. At first follow-up visit, 71.4% in Group 3 versus 62.0% in Group 2 subjects reported at least one of four positive behavioral changes (p < 0.001). Increase in reading food labels for calorie and fat content was the most common change and higher in Group 3 (Group 3 from 60.9% to 79.1%; Group 2 from 67.6% to 77.5%; p < 0.001). Final evaluation showed significant increase in self-reported exercise in Group 3 only (from baseline 52.9% to 68.3%; p < 0.05). Group 3 reported higher increase in median number of donations/year during study enrollment (6.8 [IQR, CONCLUSION: Positive donor reinforcement (double vs. routine points) resulted in better self-reported health maintenance behavior and increased donation rates. C ardiovascular disease (CVD), the leading cause of death in the United States, is accountable for one in four deaths. 1, 2 The primary risk factors for CVD include dysglycemia, high blood pressure, elevated triglyceride levels, low high-density lipoprotein (HDL) cholesterol levels, and obesity (especially central adiposity).
Blood donors are generally presumed to be "healthy"; however, they may have CVD risk. Previous studies have investigated the use of CVD screening to increase blood donation rates and improve public health. [3] [4] [5] Blood centers can play an important role in donor health and provide donors with baseline and follow-up CVD risk factor profile information and can in turn promote healthy behaviors. Donor CVD risk screening has two potential benefits. First, it provides donors with information about their CVD risk factor profile, thus prompting them to pursue and sustain healthy behaviors with a goal to improve their CVD health. Second, it establishes a robust and long-standing relationship between the blood center and donors to potentially increase their donation frequency and preserve their donor eligibility and thus can work as a donor recruitment and retention strategy.
Blood centers typically incentivize the donors through different programs such as gifts or reward points. [7] [8] [9] Whether additional incentive points compared to routine points to donors who maintain or improve good health practices based on their CVD screening results lead to continued improvement in healthy behavior as well as increased donation rates remains to be proven. To assess this relationship, we designed a controlled trial which offered CVD screening with extra bonus incentive points if the donor continued to be healthy or if the CVD profile improved compared to the CVD screening with regular incentives and no CVD screening with regular incentives.
MATERIALS AND METHODS
In our center, blood donors participate in the Advantage Point Program, which gives donors points at baseline for each donation. The points are redeemable for a variety of charitable donations, gifts, or gift cards (https://www.nybc. org/donate-blood/donor-advantage/).
This study was planned as a three-arm prospective controlled randomized study with the following groups:
• Group 1 (control group)-no CVD screening, routine points, and no bonus points offered • Group 2-CVD screening, routine points, and no bonus points; and • Group 3-CVD screening, routine points, and bonus (double) points based on CVD screening measurement outcomes at each visit if CVD screening measures demonstrated either 1) improvement or 2) maintenance of their CVD risk profile (if already within normal limits).
Each arm of the study was associated with a unique fixed donor site. This allowed us to recruit donors who came in to donate of their own accord rather than coming to the blood drives at their company or house or worship where donation would be limited to scheduled blood drives. All sites had similar donation volumes and significant portion of regular donors with similar annual donation rates and donor demographics. Donors in Groups 2 and 3 could only receive CVD screening in follow-up collections if they returned to their assigned fixed site location. The donors formally consented to be in the study and the study was approved by New York Blood Center's Institutional Review Board. The field work of the study was completed from October 2012 to June 2015.
During the study period, dedicated study facilitators recruited presenting donors at the Group 2 and 3 sites. The collections staff then assumed program execution through follow-up visits. Follow-up continued until enrolled donors had at least 2 years in the program after recruitment. At the time of recruitment, participants in Groups 2 and 3 had an identification sticker placed on their donor card, which is presented at each donation visit, to communicate their participation in the program to collection staff. At the initial visit a brief CVD health questionnaire was administered, asking about smoking habits and previously diagnosed CVD conditions and medications (Appendix S1, available as supporting information in the online version of this paper). A shorter CVD health questionnaire, asking about visits to health care provider and changes in lifestyle habits, was administered at each subsequent visit (Appendix S2, available as supporting information in the online version of this paper). As part of routine donation, participants have their blood pressure taken and for participants in Groups 2 and 3 an extra blood sample (7 mL) was drawn to measure total cholesterol, HDL, and hemoglobin (Hb) A1C levels. Because of the need for a blood sample, only donors who were eligible to donate received CVD blood screening results.
Results of laboratory tests were communicated to donors via mailed letter and posted within secure, password-protected donor accounts on the donor relationship management website. From the website, the donor could access additional materials about cardiovascular health profile, normal ranges, and other health-related online tools. The notification letters also included the Web link for this information. This has been presented in prior publications. 10 The primary outcome of the study was to determine whether or not Group 3 had measurable CVD improvements compared to Group 2. CVD improvements were measured by 1) improvement in laboratory values; 2) positive change in donor's health maintenance practices, which was assessed using self-reported behavioral change in one or more of the following activities: a) reading food labels for calorie and fat content, b) exercising daily, c) reduced fat intake, and d) increase in eating fruits and vegetables; and 3) improved health care-seeking behavior, which was assessed in form of donors seeking to a) schedule a physician visit primarily due to the CVD screening test results and b) resultant change in medication regimen, which could include starting, modifying, or stopping a medication. The secondary outcome was to assess the change in blood donation rates based on CVD screening and bonus points (all three groups compared).
Outcomes were analyzed at two time points, first follow-up and final follow-up visits, for Groups 2 and 3. We performed between-group comparisons between Group 2 and Group 3 at each time point, and within-group comparisons (results at first follow-up vs. final follow-up) for both Group 2 and Group 3 participants.
Of note, the donors are a combination of 1) whole blood donors and 2) automated red blood cell (RBC), plasma, or platelet (PLT) donors as detailed below in results section. Our final results were not stratified by "donation type" as the interventions of CVD screening and bonus points were not dependent on being a whole blood or a specific component donor.
Statistical analysis
Statistical analyses were performed using computer software (SAS, Version 9.4, 2012, SAS Institute Inc.). Unadjusted demographic and outcome comparisons were performed using chi-square, t, Fisher's exact, and Wilcoxon rank-sum tests. Normality assumption was applied for above tests. When normality assumption was not valid, nonparametric tests including Kruskal-Wallis (distribution free) were used to assess for significant differences on continuous dependent variables. Paired t testing, McNemar's test, standardized differences, and binomial-family generalized estimating equation regression with logit link and robust standard errors were used for analysis of outcomes. A two-sided p-value of less than 0.05 was used as the significance threshold.
RESULTS

Donor demographics at baseline
A total of 570 donors were enrolled in the study. The donors are a combination of 1) whole blood donors (57.62%) and 2) automated RBCs, plasma, or PLT donors (42.38%). There was one therapeutic whole blood donor in the study (included as whole blood). Of these, Group 1 included 290 controls selected from a pool of donors, Group 2 included 134 donors, and Group 3 included 146 donors (Table 1) . Group 1 had almost equal representation of males and females while Group 2 and Group 3 had slight male preponderance. The most common ethnicity among all donor groups was white (65%), consistent with typical blood donor demographics. The median number of baseline blood donations before enrollment were comparable between the three groups: Group 1 had 4.4 (IQR, 2.7-8.0), Group 2 had 4.9 (IQR, 3.5-10.2), and Group 3 had 4.6 (IQR, 3.2-7.1; p = 0.176).
Baseline CVD risk factor identification at the time of recruitment
There were no differences in the baseline diastolic and systolic blood pressure measurements in the three groups and comparable percentages of participants were normotensive, prehypertensive, and hypertensive, respectively. The baseline body mass index (BMI) was also comparable for each of the three groups. Analyzing by BMI categories (normal, overweight, or obese), there was no significant differences in the percentage of subjects in each category between the three arms at time of recruitment ( Table 1) .
The results of the health questionnaire, which was administered at the time of initial donation for Groups 2 and 3 only, showed comparable results ( Table 2 ). For selfreported risks, a similar percentage of participants in both groups reported having high cholesterol with a comparable percentage of participants reported being on cholesterollowering medications. Likewise, a comparable percentage for participants reported having history of high blood pressure or taking blood pressure-lowering medications. Other risk factors such as diabetes, stroke, and history of angioplasty were reported by only a few participants. None of participants in Group 2 reported being an active smoker, and 25 (22%) participants identified themselves as past smokers, while in Group 3, five (5%) participants reported active smoking and 24 (21%) participants identified themselves as past smokers. Approximately half of participants reported taking vitamin supplements. A minority of participants (10% to 25%) either did not report seeing a physician regularly or did not visit a physician within the past 12 months (Table 2) .
Self-reported behavioral change for CVD risk: first follow-up
On first follow-up visit, in Group 2, 62% subjects reported at least one behavioral change (mean number of behavioral changes, 1.6) and in Group 3, 71.4% of the subjects reported at least one behavioral change (mean number of behavioral changes, 1.8; p < 0.001). The most common change was reading food labels for calorie and fat content with both groups reporting a significant increase in the number of participants reading food labels for calorie and fat content: Group 2, 67.6% at baseline to 77.5% at first follow up; and Group 3, 60.9% at baseline to 79.1% at first follow-up (p < 0.001). No significant improvements were seen in daily exercise, reduced fat intake, or eating more fruits and vegetables at first follow-up visit (Table 3) . Among the five participants who self-reported as current smokers at baseline, one participant reported quitting smoking at first follow-up.
Self-reported behavioral change for CVD risk: final follow-up
On final follow-up visit, there was a significant increase within each group in participants who reported at least one positive behavioral change from first follow-up assessment (Group 2, increase to 77.9%; and Group 3, increase to 81.3%; p < 0.001). On final follow-up, both groups showed an additional significant increase in participants reading food labels for calorie and fat content (Group 2, increase to 87.4%; and Group 3, increase to 84.6%; p < 0.001).
In addition, a significant increase in report of exercising daily was noted only among Group 3 participants with an increase from 52.9% to 68.3% (p < 0.05). In contrast, Group 2 participants did not report a significant change in exercising behaviors.
For both Group 2 and Group 3, at final follow-up, there was also a nonsignificant increase in participants reporting reduced fat intake (Group 2, from 58.0% to 67.9%, vs. Group 3, from 53.3% to 59.1%; Table 4 ). In the Group 3, there were no additional reports of quitting smoking between the first and last follow-up duration. 
Comparison in laboratory values at first and final follow-up visits
Laboratory values including HDL, cholesterol, and HbA1C were recorded in Groups 2 and 3 only at baseline and follow-up visits. There was small but nonsignificant increase in mean HDL levels for both Group 2 and Group 3 at first and long-term follow-up. There was a small but nonsignificant decrease in mean cholesterol levels at short-and (Tables 3 and 4) .
Follow-up for treating CVD risk factors
Both Group 2 and Group 3 participants reported a small but nonsignificant increase in having scheduled a visit to a physician since enrolling in the CVD screening program. At first follow-up, 22.1% of the participants in Group 2 and 23.9% in Group 3, reported seeing a physician since initiation of the CVD screening program This further increased to 31.9% and 37.6%, respectively, on final follow-up visit. Further, some participants in both groups reported the primary reason for visiting the physician being because of the screening program alone. While there was no significant change in seeing a physician between first and final follow-up in Group 2, in Group 3 about 6.4% subjects additionally reported seeing a physician primarily due to being enrolled in the CVD screening program (p = 0.314). Overall, this represents a statistically non-significant increase in Group 3 participants seeking medical attention as result of the screening as follow-up continued (Table 5) . At first and final follow-up, a small percentage of participants in Group 2 and Group 3 reported altering (starting/modifying/stopping) their medication regimen for cholesterol, hypertension, or other etiologies although these changes were not significant (Table 6 ).
Blood donation rates before enrollment and during study duration (Table 7 ; Fig. 1 ).
DISCUSSION
The results of this CVD risk assessment and prevention study for blood donors suggest that positive reinforcement through administration of double points leads to 1) improvement in health maintenance behavior and practices with continued improvement with longer follow-up, 2) improved health care-seeking behavior, and 3) significantly increased donation rates for blood donors when compared to the control group or donors receiving regular bonus points only. Coronary heart disease continues to be a leading cause of morbidity and mortality among adults all over the world. Blood donors are presumed to be "healthy." In prior studies, we found that 61% of blood donors had BMIs of more than 25, 29% had high total cholesterol, and 31% had lower-than-recommended HDL levels. Other findings included that 47% of had borderline blood pressure values and 12% had hypertensive values. Thus, donors may have underlying heart disease that the blood centers can help recognize. There are few studies assessing the health risk in donors. In a recent prospective, epidemiologic, transversal study performed in more than 500 volunteer blood donors in Argentina who were otherwise believed to be healthy, using a risk factor scoring for prediction of coronary heart disease using the Framingham score, the healthy donors who were identified to meet the definition of metabolic syndrome (MS) showed three times the odds of developing cardiovascular events over the next 10 years compared to those who did not have these risk factors. 11 In another crosssectional study in healthy Mexican donors, MS was reported to be very common with an estimated prevalence of 54.4%. 12 In addition, blood donation frequency and intensity have not been shown to be associated with a prevalence of MS. 13 In another cross-sectional study using the US National Health and Nutrition Examination Survey, the prevalence of obesity was 25.1%, 25.7% in men and 24.4% in women. Obesity was associated more with middle age (age 50-59 years) than less than 20 years and with black and Hispanic race/ethnicity compared with white race/ethnicity and inversely associated with higher educational attainment (college degree vs. high school).
14 Identification of the prevalent risk factors are the key first step toward implementing any preventive measures or changes in lifestyles and eventually controlling or eliminating risk factors to be free from diseases like diabetes, hypertension, and obesity. Our group and other studies have previously shown that health screening of donors is feasible. 10, 15 Cardiovascular disease screening of blood donors have been suggested to be an incentive to donate blood previously. Our current study's results provide objective evidence of higher rates of donation for donors who underwent CVD screening compared to those who did not and even higher rates of donation in donors who received double bonus incentive points maintained or improved their cardiovascular risk profile based on the results of the screening and thus further reaffirming the positive role of the health screening and incentives. The improvement in mean donation rates were sustained long term during 2 years of follow-up for this study population.
There are limitations of the study that need to be duly acknowledged. Due to a community-or center-based design, participants in Groups 1, 2, and 3 may not be like each other. Some of the observed differences in outcomes could be attributable to the baseline demographic differences between participants. However, as shown in Tables 1  and 2 , none of the baseline characteristics showed significant differences between the various groups. The randomization design of the study should account for many of these confounding variables. Also, as part of study design, a priori decision was taken to analyze data at first follow-up visit and final visit at end-of-study enrollment only. Outcomes were not assessed by interdonation intervals and individualand group-level differences in interdonation intervals could possibly affect some of the results.
The reason for effectiveness of the bonus points is not known. However, given the increase in monetary worth by doubling of the redemption points is practically minimal, the recognition and positive rewarding of the healthy behavioral practices and maintaining or improving one's health likely was actual incentive for the donors.
Thus, we propose that positive reinforcement with double points versus routine points for blood donors for maintaining or improving health status based on CVD screening results leads to an improvement in self-reported health maintenance practices and improved donation rates for blood donors. A longer follow-up and further prospective validation of these findings and correlation with objective criteria for cardiovascular health including clinical and laboratory variables will be key to suggest a wider adoption of such strategies by blood centers.
